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Aims: It has been reported that endothelin-1 (ET-1) overproduction and reduced nitric oxide (NO) produc-
tion are closely related to the progression of renal diseases. In the present study, we examined the interrela-
tion between ET-1 and NO system using rats treated with the combination of deoxycorticosterone acetate
(DOCA)-salt and a non selective NO synthase inhibitor Nω-nitro-L-arginine (NOARG).
Main methods: Rats were treated with DOCA–salt (15 mg/kg, plus drinking water containing 1% NaCl) for two
weeks, and then additional treatment of NOARG (0.6 mg/ml in the drinkingwater) was performed for three days.
Key ﬁndings: Combined treatment of DOCA–salt and NOARG drastically developed the severe renal dysfunction
and tissue injury. This treatment additionally enhanced renal ET-1 production compared to the rats treated
with DOCA–salt alone, whereas a selective ETA receptor antagonist ABT-627 completely prevented renal dys-
function and tissue injury. On the other hand, combined treatment of DOCA–salt and NOARG induced the phos-
phorylation of inhibitory protein kappa B (IκB), followed by the activation of nuclear factor-kappa B (NF-κB) in
the kidney. In addition, pyrrolidine-dithiocarbamate completely suppressed not only NF-κB activation but also
renal dysfunction and ET-1 overproduction.
Signiﬁcance: These results suggest that NF-κB/ET-1/ETA receptor-mediated actions are responsible for the in-
creased susceptibility to DOCA–salt induced renal injuries in the case of reduced NO production.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Hypertension is one of the lifestyle-related diseases, and its onset
and progression are due to the interplay of genetic predispositions
and/or environmental factors (excessive salt intake, stress, etc.). It
has also been well known that other causative factors such as activa-
tion of the renin–angiotensin system, the increase in oxidative stress,
and overactive sympathetic nervous system are responsible for the
development andmaintenance of hypertension. Recently, themorbidity
in patients with chronic kidney disease (CKD) has dramatically multi-
plied in association with the increase in lifestyle-related diseases such
as cardiovascular disease and diabetes. CKD can ultimately induce hy-
pertension regardless of any kind of it andhypertension itself is involved
in CKD progression as a powerful precipitating factor (Martínez-
Maldonado, 2001). Therefore, proper management of blood pressure
and renal function is extremely important to prevent CKD-induced hy-
pertension or hypertension-induced CKD progression.l and Molecular Pharmacology,
sahara, Takatsuki, Osaka 569‐
sumura).
-NC-ND license.Endothelin-1 (ET-1) ismainly producedby vascular endothelial cells
(ECs) and has a powerful effect on circulatory system (Yanagisawa et
al., 1988). Therefore, the role of ET-1 as the etiology or precipitating fac-
tor has been paid attention in several cardiovascular diseases. In fact,
there are numerous reports about effective treatment targeted at ET-1
in pulmonary hypertension (Nishida et al., 2004), and acute and chronic
kidney diseases (Kuro et al., 2000; Okada et al., 2004). Our previous
studies have also shown the pathophysiological role of ET-1 and its re-
ceptors in salt-sensitive hypertension (Matsumura et al., 1999, 2000).
It has been well known that nitric oxide (NO) is one of the major
relaxation factors derived from vascular ECs and that decline of its
production is closely involved in the progression of renal diseases in
an experimental CKD animal models (Aiello et al., 1997; Roczniak et
al., 1999; Erdely et al., 2004) or CKD patients (Schmidt et al., 1999;
Schmidt and Baylis, 2000; Wever et al., 1999). Our previous study
has shown that renal mass reduction in endothelial NO synthase
(eNOS) knock-out mice showed notable renal dysfunction compared
with wild-type mice (Yamashita et al., 2008). In addition, it has been
reported that NO release is decreasing in isolated perfused kidney
of deoxycorticosterone acetate (DOCA)–salt hypertensive rats
(Hayakawa et al., 1994), and that the administration of L-arginine sup-
presses renal dysfunction and tissue damage in spontaneously hyper-
tensive rats (SHR) (Ono et al., 1999; Miloradović et al., 2008). Taken
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hypertension is based on the decrease in renal NO production.
In the present study, to clarify the pathopyhsiological role of ET-1
and NO in CKD, we examined the interactions of ET-1 and NO produc-
tion during the onset and development of kidney disease using
DOCA–salt hypertensive rats.
Methods
Animals
Male Sprague–Dawley (SD) rats (SLC, Inc., Hamamatsu, Japan)
were used. The animals were housed in an animal room under the fol-
lowing conditions: temperature, 24±1 °C; relative humidity, 55±5%;
and 12-h light/dark cycle. The animals received standard chow (NMF;
Oriental Yeast Co., Ltd., Tokyo, Japan) and drinkingwater ad libitum. Ex-
perimental protocols and animal caremethods in the experimentswere
approved by the Experimental Animal Committee at Osaka University
of Pharmaceutical Sciences.
Drugs
A selective ETA antagonist ABT-627 (Abbott Laboratories, IL, USA)
was dissolved in a mixture of 10% ethanol, 40% propylene glycol, and
50% distilled water. A nonselective NOS inhibitor Nω-nitro-L-arginine
(NOARG, Peptide Institute Inc., Osaka, Japan) and a nuclear factor-
kappa B (NF-κB) inhibitor pyrrolidine dithiocarbamate (PDTC, Sigma
Chemical Co. St. Louis, MO, USA) were dissolved in distilled water
and saline, respectively. Other chemicals were obtained from Wako
Pure Chemical Industries (Osaka, Japan).
DOCA–salt treatment in rats
Male SD rats (6-weeks old) were anesthetized with sodium pento-
barbital (50 mg/kg, i.p.), and the right kidney was removed via a right
ﬂank incision. After a 1-week postsurgical recovery period, rats were
treated twice weekly with DOCA suspended in corn oil, which was
administered subcutaneously (15 mg/kg), and 1% NaCl was added to
their drinking water. These rats were randomly separated into four
groups: i) DOCA–salt alone, ii) DOCA–salt+NOARG (0.6 mg/ml in
drinking water), iii) DOCA–salt+NOARG+ABT-627 (10 mg/ml/kg,
b.i.d., p.o.), iv) DOCA–salt+NOARG+PDTC (100 mg/ml/kg, i.p.).
Systolic blood pressure (SBP) was monitored with the tail cuff
method and a pneumatic pulse transducer (BP-98A, Softron, Tokyo,
Japan).
Renal functional parameters
Blood urea nitrogen (BUN), protein, and creatinine levels in plasma
or urine were determined using the BUN-Test-Wako, Total Protein-
Test-Wako, and Creatinine-Test-Wako (Wako Pure Chemical Indus-
tries), respectively.
Measurement of NO metabolites (nitrite (NO2
−) and nitrate (NO3
−))
NOx (NO2− and NO3−) in the urine sample was separated and quan-
titated by the use of the high performance liquid chromatography-
Griess system (ENO-20, EICOM) as previously described (Yamashita
et al., 2003).
Isolation of total RNA, synthesis of cDNA, and quantitative real-time
reverse transcriptase-PCR (RT-PCR) analysis
Total RNA was extracted from isolated rat kidney using RNAiso
Plus (Takara Bio Inc., Shiga, Japan), according to the manufacturer's
instructions. Real-time RT-PCR analysis was performed using SYBR®PrimeScript® RT-PCR Kit (Takara Bio Inc.). Rat ET-1, EDNRA, EDNRB,
and GAPDH primer sequences are as follows: forward primer,
5′-TTGCTCCT GCTCCTCCTTGAT-′3′ (ET-1), 5′-CAGGAGCAGAACCACAACA
CA-3′ (EDNRA), 5′-GATACGACAACTTCCGCTCCA-3′ (EDNRB), and 5′-
CGGTGTGAACGGATTTGG-3′ (GAPDH); reverse primer, 5′-TAGA-
CCTAGAAGGGCTTCCTAGT-3′ (ET-1), 5′-TGCTGCGTGACCGTTTCA-3′
(EDNRA), 5′‐GTCCACGATGAGGACAATGAGA-3′ (EDNRB), and 5′-
TGAAGGGGTCGTTGATGG-3′ (GAPDH). Comparison to GAPDH values
was carried out for normalization. Relative expression levels in each
sample were determined by comparison with the standard using the
LightCycler3 Front software (Roche Diagnostics K.K., Tokyo, Japan) for
analysis.
ET-1 measurement
ET-1 was extracted from the kidney according to our method
(Yamashita et al., 2003). Radioimmunoassay for tissue ET-1 was per-
formed with the use of ET-1 antiserum (a generous gift from Dr.
Marvin R. Brown, University of California, San Diego), which does
not cross-react with big ET-1.
Western blot analysis
Isolated rat kidneys were frozen under liquid nitrogen, and ho-
mogenized as previously described (Satake et al., 2008). The homog-
enate was then centrifuged, stored at −80 °C, and used for western
blotting. Equal amount of protein was fractionated using 7.5% or
12% SDS-polyacrylamide gels. After transferring to nitrocellulose
membrane and blocking, the blots were incubated with primary anti-
bodies (phosphorylated-eNOS (Ser1177) and phosphorylated-IκBα
(Ser32), Cell Signaling Technology, Beverly, MA, USA; eNOS, nNOS,
and actin, BD Biosciences, San Jose, CA, USA; IκBα, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), and then incubated secondary antibodies.
Detectionwas carried out using an enhanced chemiluminescencewest-
ern blotting kit (GEHealthcare UK Ltd., Amersham Place, Little Chalfont,
Buckinghamshire, UK) and quantiﬁed by using the NIH IMAGE.
Histological studies
The kidney of each ratwas preserved in phosphate-buffered 10% for-
malin, after which the tissues were chopped into small pieces, embed-
ded in parafﬁn, cut at 4 μm, and stained with hematoxylin and eosin.
Preparation of nuclear extracts and electrophoretic mobility shift
assay (EMSA)
Nuclear extracts were prepared from kidney by using our method
(Ohkita et al., 2002a). The nuclear extracts (2 μg protein) were used
for EMSA. Double-stranded oligonucleotides containing the most
common NF-κB consensus binding site 5′-AGT TGA GGG GAC TTT CCC
AGG C-3′ were end-labeled with [γ-32P] ATP, using T4 polynucleotide
kinase. DNA–protein complexes were resolved on 6% nondenaturing
polyacrylamide gels. After electrophoresis, gels were dried and exposed
to imaging plates. The protein–DNA complexes were visualized using
autoradiography.
Statistical analysis
All values were expressed as mean±SEM. Relevant data were
processed by InStat (GraphPad Software Inc., San Diego, CA). For sta-
tistical analysis, we used the unpaired Student's t-test for two-group
comparison and one-way analysis of variance followed by Bonferroni
tests for multiple comparisons. Differences were considered signiﬁ-
cant at Pb0.05.
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The changes of renal function and NO production in DOCA–salt-induced
hypertensive rats
We ﬁrst examined the changes of systemic blood pressure, renal
function, and renal ET-1 and NO production in DOCA–salt hyperten-
sive rats. DOCA–salt treatment time-dependently produced signiﬁ-
cant increases in SBP (Fig. 1A), and there was a remarkable
difference between sham group (106.9±9.0 mm Hg, n=5) and
DOCA–salt treatment group (195.1±11.9 mm Hg, n=7, Pb0.01 ver-
sus sham group) at eight weeks. DOCA–salt treatment gradually de-
creased creatinine clearance and showed a statistically signiﬁcant
difference at both ﬁve and eight weeks compared to sham group (re-
spective values were 2.64±0.75 versus 4.43±0.49 at ﬁve weeks,
Pb0.01; 2.22±1.03 versus 4.43±0.42 at eight weeks, Pb0.01). Uri-
nary excretion of protein (UproV) rapidly increased two weeks after
DOCA–salt treatment, and thereafter its difference between both
groups became more considerable (Fig. 1B). In addition, the differ-
ence of renal ET-1 content between both groups was more consider-
able at ﬁve and eight weeks (Fig. 1C). On the other hand, NOx
excretion in DOCA–salt treated rats temporarily increased at two
weeks and thereafter showed a signiﬁcant decrease at eight weeks
compared with sham (Fig. 1D). The same change was observed not
in eNOS but in phosphorylated-eNOS (p-eNOS) protein levels in
renal tissue (Fig. 1E and F). Furthermore, the nNOS protein expression
levels tended to decrease in the kidney of DOCA–salt hypertensive
rats only at eight weeks (Fig. 1G), though there was no signiﬁcant
difference.90
110
130
150
170
190
210
230
0 1 2 3 4 5 6 7 8
0
SB
P 
(m
mH
g)
A
**
** **
0
200
400
600
800
1000
1200
0 1 2 3 4 5
Up
ro
V 
(m
g/2
4 h
r/k
g)
B
D
0
0.2
0.4
0.6
0 1 2 3 4
p-
eN
O
S/
ac
tin
*
E
**
(w)
0
1
2
3
4
5
6
7
0 1 2 3 4 5 6 7 8
u
rin
ar
y 
N
O
x 
e
xc
re
tio
n
(m
mo
l/2
4 h
r) *
**
(w)
*
0
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8
n
NO
S 
/ a
ct
in
(w)
G
Fig. 1. Effects of DOCA–salt treatment on SBP (A), UproV (B), renal ET-1 content (C), urinar
sham (n=4–5); ●, DOCA–salt (n=5–7). Each point and bar represents the mean±S.E.M.The renoprotective effect of ABT-627 on DOCA–salt and NOARG-induced
hypertensive rats
To clarify whether endogenous NO functions as a protective factor
against the development of renal disorders by ET system in DOCA–salt
rats at two weeks, we investigated the effects of NOARG on ET-1 pro-
duction, ET receptors, and renal function in DOCA–salt hypertensive
rats. Two weeks after DOCA–salt treatment, the signiﬁcant increase in
renal ETA receptor mRNA expression was observed in DOCA–salt-treated
group (Fig. 2C), but therewas no signiﬁcant difference in ET-1 production
andETB receptormRNAexpression levels in the kidney (Fig. 2A, B, andD).
On the other hand, additional administration of NOARG for three days re-
markably enhanced not ET receptors but ET-1 production compared to
the rats treated with DOCA–salt alone (Fig. 2A and B). In addition, al-
though SBP, BUN, and UproV in DOCA–salt-treated rats before treat-
ment of NOARG were 144.48±10.51 mmHg, 17.9±1.3 mg/ml, and
214.48±54.7 mg/24 h/kg, respectively, the combined treatment of
DOCA–salt and NOARG drastically elevated BUN and UproV (Fig. 3A
and B) and caused an extremely severe tissue injury such as congestion
in the cortex and tubular necrosis in the outer stripe of the outer zone of
the medulla of the kidney (Fig. 3C). Furthermore, a selective ETA antag-
onist ABT-627 had no signiﬁcant effect on ET-1 and both on ET recep-
tors' mRNA expression in the kidney (data not shown), but ABT-627
signiﬁcantly prevented renal dysfunction and tissue injury (Fig. 3).
The effects of PDTC on DOCA–salt and NOARG-induced hypertensive rats
It has been reported that a transcription factor NF-κB contributes
to endothelial dysfunction and the pathogenesis and development6 7 8
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647K. Kimura et al. / Life Sciences 91 (2012) 644–650of various cardiovascular diseases (Tak and Firestein, 2001; Tedgui
and Mallat, 2001). We also previously reported that NF-κB is one of
the regulatory factors in ET-1 production (Ohkita et al., 2002a,b).
Thus we examined the involvement of NF-κB in ET-1 overproduction
seen in the kidney of DOCA–salt and NOARG-treated rats. Two weeks
after DOCA–salt treatment, the additional administration of NOARG
for three days increased NF-κB DNA binding activity in the kidney
(Fig. 4A). This combined administration also induced the decrease
in IκBα protein levels and the increase in phosphorylated-IκBα pro-
tein levels (Fig. 4B). These changes were markedly suppressed by
PDTC. In addition, PDTC exhibited signiﬁcant inhibitory effects on
DOCA–salt and NOARG-induced ET-1 overproduction in the kidney
(Fig. 4C) and renal dysfunction (Fig. 4D). Moreover, we also observed
the suppressive effect of ABT-627 on DOCA–salt- and NOARG-induced
NF-κB activation (the NF-κB binding activity in DOCA–salt+NOARG
and DOCA–salt+NOARG+ABT-627 groups was 230.05±40.74%
(n=6) and 141.38±4.29% (n=3), respectively).A
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Fig. 3. Effects of ABT-627 on DOCA–salt and NOARG-induced renal dysfunction (A and B)
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in the medulla.Discussion
Pathophysiological role of ET-1 and NO is so far aggressively ex-
amined by using various experimental animal models. In CKD ani-
mal models or CKD patients, it has been reported that ET-1
overproduction (Goddard et al., 2004; Dhaun et al., 2006) or decline
of NO production (Aiello et al., 1997; Roczniak et al., 1999; Schmidt et
al., 1999; Schmidt and Baylis, 2000; Wever et al., 1999; Erdely et al.,
2004; Baylis, 2008) in the kidney contributes to pathological formation.
In the present study, we investigated the interaction of ET-1 and NO
production in CKD by using DOCA–salt hypertensive rats.
In DOCA–salt hypertensive rats, we observed temporal increase in
urinary NOx excretion at two weeks and then gradual decrease in it
until eight weeks. These results are consistent with the previous re-
port by Allcock et al. (1999). Many reports have demonstrated that
eNOS activity ﬂuctuates depending on the phosphorylation or de-
phosphorylation in several areas of serine and threonine residues,0
200
400
600
800
1000
Up
ro
V 
(m
g/2
4h
r/k
g)
*
†
 NOARG DOCA-salt + NOARG + ABT-627
B
DOCA-salt
+ NOARG
DOCA-salt
+ NOARG + ABT-627
and tissue injury (C). Each column and bar represents the mean±S.E.M. (n=6–9)
NOARG. Arrows indicate representative congestion in the cortex and tubular necrosis
AC D
B
Fig. 4. Effects of PDTC on DOCA–salt and NOARG-induced NF-κB DNA binding activities (A), IκBα and phosphorylated-IκBα (p-IκBα) expression (B), renal ET-1 mRNA expression
and ET-1 content (C), renal dysfunction (D). Each column and bar represents the mean±S.E.M. (n=3–6) **Pb0.01 compared with DOCA–salt, #Pb0.05, ##Pb0.01 compared with
DOCA–salt+NOARG.
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plays an important role in the regulation of its activity (Dimmeler et
al., 1999; Fulton et al., 1999; Mount et al., 2007). In the present
study, the change of phosphorylated-eNOS protein levels in the kid-
ney was similar to that of urinary NOx excretion after DOCA–salt
treatment. We observed also that phosphorylated-eNOS protein
levels in the kidney of DOCA–salt hypertensive rats correlated closely
with the degree of renal dysfunction (data not shown). Moreover, ad-
ditional treatment of NOARG for just three days only caused very se-
vere renal dysfunction and tissue injury. Taken together, it is most
likely that transient increase in phosphorylated-eNOS protein levels
and urinary NOx excretion seen at two weeks is based on the compen-
satory reaction to suppress the progress of DOCA–salt-induced renal
dysfunction. On the other hand, atﬁveweeks after DOCA salt treatment,
eNOS protein expression levels signiﬁcantly increased, but urinary NOx
excretion did not. Herrera et al. (2006) has reported that the ability of
NO production in the kidney is dependent on phosphorylated-eNOS
protein rather than eNOS protein levels. Thus, the increase in eNOS pro-
tein levels observed at ﬁve weeks seems not to directly reﬂect NO
production.
It has been reported that nNOS, which is abundantly expressed in
kidney medulla (Kakoki et al., 2001), has a close relationship to the
progression of CKD (Roczniak et al., 1999; Erdely et al., 2007). We
also examined nNOS protein expression levels in the kidney of
DOCA–salt hypertensive rats and observed decreasing trend of it
only at eight weeks. Therefore, although there is a possibility that
the reduced ability of NO production is partly based on nNOS protein
levels and/or its activity, the pathological role of nNOS in DOCA–salt
hypertensive rats seems to need further investigation.On the other hand, renal ET-1 content in DOCA–salt hypertensive
rats signiﬁcantly increased after two weeks. This increase also went
with increment of urinary protein excretion. These results suggest
that ET-1 overproduction in the kidney is closely related to renal dys-
function. In addition, there was a negative correlation between ET-1
content and phosphorylated eNOS protein levels in the kidney (data
not shown). Therefore, it is most likely that renal dysfunction seen
in DOCA–salt hypertensive rats is based on imbalance of ET-1 and
NO production and that the increase in NO production at two weeks
is compensatory reaction to suppress ET-1 production. Based on
these ﬁndings, we examined the effect of pharmacological reduction
of NO production on DOCA–salt hypertensive rats. As a result, renal
ET-1 content exhibited no change at two weeks after DOCA–salt
treatment, but additional treatment of NOARG increased both ET-1
mRNA expression and renal ET-1 content. These changes are qualita-
tively consistent with the previous report showing that NOS inhibi-
tion results in ET-1 overproduction in renal tubular and glomerular
cells (Slowinski et al., 2007) or glomerular afferent arterioles
(Tharaux et al., 1999). In addition, DOCA–salt and NOARG-induced
renal dysfunction and tissue damage were almost completely
suppressed by ABT-627. These ﬁndings suggest that the enhancement
of renal NO production at two weeks serves for the inhibition of ET-1
production and suppresses the development of renal dysfunction. Fur-
thermore, it is reasonable to consider that ET-1 deteriorates renal func-
tion via ETA receptor when renal NO production is diminished.
As combined treatment with DOCA–salt and NOARG for three days
rapidly debilitated rats, we could not measure the change of blood
pressure in those animals. On the other hand, the administration of
L-NAME, which is another nonselective NOS inhibitor, has been
649K. Kimura et al. / Life Sciences 91 (2012) 644–650reported to provide further increase in blood pressure in DOCA–salt hy-
pertensive rats (Alvarez et al., 2000; Gracia et al., 2000; Rodriguez-
Gomez et al., 2003). Slowinski et al. (2007) also reported that the ad-
ministration of L-NAME in prepro ET-1 promotor-lacZ-transgenic mice
resulted in the signiﬁcant elevation of blood pressure. Therefore, addi-
tional treatment of NOARG in this experiment might have immediately
raised the blood pressure compared with DOCA–salt alone rats. In addi-
tion, each effect of NOARG and ABT-627 on renal functions seems to be
attributable to the changes of blood pressure by these agents, but fur-
ther detailed inspection is required about the relationship between
blood pressure and renal dysfunction.
It has been shown that a transcription factor NF-κB, which regu-
lates many gene expression including cytokines and adhesion mole-
cules, ampliﬁes endothelial dysfunction and the progress of organ
damage in the pathogenesis and development of various cardiovascu-
lar diseases such as hypertension and atherosclerosis (Tak and
Firestein, 2001; Tedgui and Mallat, 2001). In fact, there are several re-
ports indicating that NF-κB activation in renal tissue was observed in
DOCA–salt hypertensive rats (Beswick et al., 2001), renal mass reduc-
tion model rats (Fujihara et al., 2007), and SHR (Rodríguez-Iturbe et
al., 2005), and that administration of NF-κB inhibitors suppressed
the increase in blood pressure and renal dysfunction seen in those an-
imals. In addition, Ammarguellat et al. (2002) showed that an ETA re-
ceptor antagonist BMS 182874 suppressed NF-κB activation in the
heart of DOCA–salt hypertensive rats. We also observed the inhibitory
effect of ABT-627 on NF-κB activation in the kidney of DOCA–salt- and
NOARG-treated rats. Thus, it is most likely that NF-κB lies down-
stream of ET-1/ETA receptor signaling pathway. On the other hand,
our previous studies have demonstrated that ET-1 production in ECs
is regulated by NF-κB (Ohkita et al., 2002a,2002b). In addition, the
κB site, a binding sequence for the activated NF-κB, is known to locate
in the promoter region of human ET-1 gene (Quehenberger et al.,
2000). We have also detected six NF-κB binding elements in 5′-
ﬂanking sequence of porcine ET-1 gene and conﬁrmed the regulation
of ET-1 promoter activity by NF-κB (unpublished observation by
Ohkita et al.). Taken together, it is reasonable to consider that NF-κB
also lies upstream of ET-1 production. Moreover, previous studies
have shown that NO suppresses NF-κB activation through the inhibi-
tion of ΙκBα phosphorylation (Katsuyama et al., 1998) or the over-
expression of IκBα protein levels (Ohkita et al., 2003). These
ﬁndings let us examine whether NF-κB mediates excessive ET-1 pro-
duction seen in DOCA–salt and NOARG-treated rats. As a result, com-
bination treatment of DOCA–salt and NOARG induced the IκBα
phosphorylation and followed by NF-κB activation, but these changes
were almost completely suppressed by PDTC. PDTC also signiﬁcantly
reduced renal ET-1 production and improved renal function and dam-
age. These results indicate that the reduction of NO production by
NOARG induces NF-κB activation and ET-1 overproduction, and that
NF-κB plays an important role in the regulation of ET-1 production
by NO. However, our present study has not identiﬁed the deﬁnite lo-
cation of excessive NF-κB activation and ET-1 production in the kid-
ney. It is widely known that renal endothelium of glomeruli,
arteries, veins, and capillaries are the principal source of glomerular
ET-1, but vascular smooth muscle cells (Tharaux et al., 1999) and
mesangial cells (Herman et al., 1998; Foschi et al., 2001) elaborate
ET-1 under certain conditions. Hsieh et al. (2000) also demonstrated
that the increase in ET-1 production in DOCA–salt treated rats was
mainly localized in the inner medullary collecting duct. Thus, further
investigation is required to clarify what kind of component cells in
the kidney is the source of excessive ET-1 synthesis induced by NF-
κB activation in DOCA–salt and NOARG-treated rats.
Conclusion
Our present study clearly shows that NO plays a renoprotective
factor in the onset and development of DOCA–salt-induced kidneydisease and that the decline of NO production accelerates the patho-
logical formation in the kidney through the activation of NF-κB/ET-
1/ETA receptor pathway.
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